Hainan buying Ecstasy

__________________________

📍 Verified store!

📍 Guarantees! Quality! Reviews!

__________________________

▼▼ ▼▼ ▼▼ ▼▼ ▼▼ ▼▼ ▼▼

▲▲ ▲▲ ▲▲ ▲▲ ▲▲ ▲▲ ▲▲

Hainan buying Ecstasy

A shortage of medical professionals and high costs, however, are key challenges. Fortunately, the ongoing digitalisation is helping to alleviate some pressure, and this is resulting in many exciting investment opportunities. The landscape has also been evolving over the past decade with concurrent advances in technology. In fact, online healthcare expenditure has increased 2. Internet hospitals can efficiently tap on services of doctors and nurses from various hospitals. Meanwhile COVID has further accelerated the digitalisation of the healthcare sector with many turning to telehealth for medical consultations. See Fig 1. Like being first? Get investment insights straight to your inbox. By subscribing, you are agreeing with the Terms of services. Online drug sales have not taken off in China for a few reasons. The traditional mindset of Chinese patients is one. Many believe that public hospitals have the best quality doctors and best available medicines, and hence avoided buying drugs online. See Fig 2. But we believe the current model is changing and that online drug sales will see strong structural growth, backed by favourable regulations. In November , the regulator issued draft regulations detailing the legal framework for online prescription drug sales and price harmonisation for drugs sold online and offline. In Apr , the Ministry of Commerce issued documents to support Hainan province as a pilot for online prescription sales. Patients that suffer from chronic illnesses will benefit greatly from this move. See Fig 3. The expansion of the 5G infrastructure network is also expected to improve and facilitate the quality of online consultations. Usually a doctor makes a diagnosis based on his or her experience and scientific evidence. This is where the AI diagnostic systems created by some Chinese technology companies fit in. Moreover, AI tools also create value for the overall healthcare industry. Patients will have more confidence in lower tier hospitals in remote areas. In return, it will ease the traffic pressure of Grade A hospitals in high tier cities. There are many AI healthcare companies in China; in , there were of them, excluding those in targeted genetic research. Among them, 55 firms are in medical imaging, representing See Fig 4. While the above narrative portends exciting investment options, it is not without challenges. Next, given the number of sub sectors within the industry, expertise of the different sub sectors is a must to single out opportunities within them. More importantly, investors must note that not all healthcare companies are high growth ones using cutting edge technology; there are many such as generic drug makers that have yet to embrace technology. Meanwhile ESG is another area we need to address among healthcare investment opportunities. Here, healthtech companies face challenges related to data, namely how data is captured, stored and used. Patient records, personal information, and genetic data have different compliance requirements, making data processing a tricky business. The role of big tech companies in healthcare is expected to grow. One key indicator that shows the growing momentum in China is the integration with telehealth platforms that are being formed by insurance companies, hospitals and government. Platforms with strong supply chain capabilities are better placed to consolidate the fragmented offline retail pharmacy market by enhancing partnerships with hospitals and quality doctors. Separately the rapid advancement of digital technologies will promote the development of new infrastructure in digital healthcare, empowering sectors including medical services, public healthcare, drug supply, health protection and healthcare management. We are only at the start of this structural growth and as more capital is invested in these areas, higher growth will be seen. But amidst all the euphoria, one needs to consider ethical issues. Big tech companies need to consciously show that patient care takes priority over using their data for monetisation. Data governance must keep abreast to ensure that ethical principles are adhered. Ultimately, AI technology should be an asset and not a liability for all. Subscribe now and turn our investment insights into your opportunities. By providing your details you are agreeing to receive emails from Eastspring Investments. All emails are in English language and has an unsubscribe link which allows you to opt out at any time. For more information, please read Eastspring Privacy Policy. Australia for wholesale clients only by Eastspring Investments Singapore Limited UEN: H , which is incorporated in Singapore, is exempt from the requirement to hold an Australian financial services licence and is licensed and regulated by the Monetary Authority of Singapore under Singapore laws which differ from Australian laws. S Securities and Exchange Commission as a registered investment adviser. European Economic Area for professional clients only and Switzerland for qualified investors only by Eastspring Investments Luxembourg S. Chile for institutional clients only by Eastspring Investments Singapore Limited UEN: H , which is incorporated in Singapore and is licensed and regulated by the Monetary Authority of Singapore under Singapore laws which differ from Chilean laws. This document is not intended as an offer, a solicitation of offer or a recommendation, to deal in shares of securities or any financial instruments. It may not be published, circulated, reproduced or distributed without the prior written consent of Eastspring Investments. Reliance upon information in this document is at the sole discretion of the reader. Investment involves risks. Past performance of and the predictions, projections, or forecasts on the economy, securities markets or the economic trends of the markets are not necessarily indicative of the future or likely performance of Eastspring Investments or any of the funds managed by Eastspring Investments. Information herein is believed to be reliable at time of publication. Data from third party sources may have been used in the preparation of this material and Eastspring Investments has not independently verified, validated or audited such data. Any opinion or estimate contained in this document may subject to change without notice. Eastspring Investments companies including joint venture companies and Prudential plc are not affiliated in any manner with Prudential Financial, Inc. China: Digitalisation hastens the healthtech boom. June 4. Fig 1: Online consultation market is expanding. Please enter the Name. Please enter valid Email. Subscribe now. Follow us :. A promising future for online drug sales. Fig 2: Online drug sales is a mere fraction of the total drug sales. Fig 3: Online retail pharmacy market set to grow strongly. The power of AI diagnostic systems to empower. Investment considerations require solid understanding. Select investor type Institutional investors Individual investors Financial agents Private investors Professional investors Others, please state. Thanks for subscribing! Thanks for signing up with us. Your already subscribed in. Open Modal. The afore-mentioned entities are hereinafter collectively referred to as Eastspring Investments.

China Permits Online Sales of Prescription Drugs Nationwide

Hainan buying Ecstasy

On Dec. To ensure safety for selling drugs online, the Measures specifies regulatory requirements for online sellers and third-party online platforms. Drug marketing authorization holders MAHs and drug suppliers with the capability to ensure drug safety can become online medical sellers. Before engaging in online sales, they shall obtain drug supplying licenses. Online drug sellers shall conduct online drug sales according to the approved supplying method and scope. Sellers should report the changes to the information within ten workdays from the day the changes take place. Though companies can sell prescription drugs online, they must comply with strict rules to avoid sales based on fake prescriptions and the repeated use of one prescription by multiple purchasers. Sellers should mark the used prescriptions to avoid repeated uses. E-commerce platform companies, also known as third-party online sale platform companies, shall fulfill the obligations, including. With the rapid growth of e-commerce, China's pharmaceutical e-commerce market expanded to billion yuan 2 The Measures repeals the ban on prescription drugs' online sales, which is expected to boost pharma e-commerce. Meanwhile, the Measures stipulates detailed obligations for online drug sellers and e-commerce platforms, especially in reviewing prescriptions and presenting prescription drug information. The companies involved in online drug sales need to follow the Measures , otherwise, they may be subject to punishments up to , yuan in fines if causing severe hazards. Grace Wang. You May Also Like. Cancel Get in Touch Now.

Hainan buying Ecstasy